Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population

Norris, Diana Islas; Photiou, Louise; Tacey, Mark; Dolianitis, Con; Varigos, George; Foley, Peter; Baker, Chris I.

doi:10.1080/09546634.2017.1329501

Cited by 18 publications

(25 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the longer-term effects of biologics, a Swedish study found that switching to biologics was associated with a sustained effect at 10 years with a PASI reduction of 82.8%, a DLQI improvement of 85.7%, and an EQ-5D improvement of 11.0% (32). A study conducted on patients with moderate-to-severe psoriasis comparing the effect of biologics with that of systemic, topical, or light treatment found that biologics resulted in an average mean reduction in DLQI of 6.6 at week 24 (33). A double blinded randomized study comparing ixekizumab with guselkumab found that 35 out of 520 (7%) of ixekizumab-and 7 out of 507 (1%) of guselkumab treated patients achieved a PASI 100 response after 4 weeks and a median PASI percentage improvement of at least 75% for ixekizumab and 50% for guselkumab (34).…”

Section: Discussionmentioning

confidence: 99%

Effect of Dead Sea Climatotherapy on Psoriasis; A Prospective Cohort Study

et al. 2020

View full text Add to dashboard Cite

Background: Dead Sea climatotherapy (DSC) is a treatment option for psoriasis in Denmark. However, the response to DSC has not been particularly well studied. Aim: We sought to determine effectiveness and response duration of DSC on psoriasis-related outcome parameters. Methods: Eighteen patients participated in a 4-week treatment program in Ein Gedi in Israel. Treatment, consisting of sun exposure and bathing, was individualized. Results: DSC was associated with a mean 13.0-point reduction (88%) in Psoriasis Area and Severity Index and a mean reduction of 2.3 (76.7%) on the 5-point Investigator's Global Assessment Scale. Furthermore, patients' quality of life improved measured by the Dermatology Quality of Life Index and EuroQol 5D index values. The mean time from treatment end to reappearance of visible skin symptoms was 93.8 days (SD: 62.5, range: 31-219 days). Conclusions: Our results confirm that DSC has an immediate effect on skin manifestations and improves quality of life, but long-term disease control is not observed.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Dead Sea Climatotherapy on Psoriasis; A Prospective Cohort Study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Furthermore, in agreement with overall sample, the highest effect was found for “symptoms and feelings” in both subgroups of patients (biologic-experienced and biologic-naïve), with the patients treated with biologics presenting significant lower values as compared to biologic-naïve patients, reinforcing the importance of biologics in the reduction of the emotional impact of psoriasis. In fact, the use of biologics has been associated with the reduction of DLQI score and, consequently, with the improvement in patients’ quality of life [35].…”

Section: Discussionmentioning

confidence: 99%

Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil

Lopes¹,

Dias

Azulay‐Abulafia³

et al. 2019

Adv Ther

View full text Add to dashboard Cite

IntroductionPsoriasis is an immune-mediated, chronic, inflammatory disease, which has a substantial humanistic and economic burden. This study aimed to assess the impact of this disease on health-related quality of life (HRQoL), work productivity, and direct and indirect costs from a societal perspective among Brazilian patients.MethodsThis is a cross-sectional, observational, multicenter study, enrolling patients with moderate to severe plaque psoriasis according to physician evaluation. Data collection was performed from December 2015 to November 2016 through face-to-face interviews using a structured questionnaire and five standardized patient-reported outcomes instruments. Direct costs were estimated by multiplying the amount of resources used (12-month recall period) by the corresponding unit cost. Indirect costs were grouped in two time horizons: annual costs (income reduction and absenteeism) and lifetime costs (demission and early retirement).ResultsA total of 188 patients with moderate to severe plaque psoriasis were included, with mean age of 48.0 (SD 13.1). “Anxiety and depression” and “pain and discomfort” were the most impaired dimensions, according to the EuroQol Five-Dimension-Three-Level (EQ-5D-3L). The highest effect was found for “symptoms and feelings” [mean (SD) 2.4 (1.7)] Dermatology Life Quality Index (DLQI) subscale. Psoriatic arthritis (PsA) presence and biologic-naïve status were associated with worse HRQoL. Presenteeism was more frequent than absenteeism, according to the Work Productivity and Activity Impairment questionnaire-General Health (WPAI-GH) [17.4% vs. 6.3%], while physical demands and time management were the most affected Work Limitations Questionnaire (WLQ) subscales [means (SD) 23.5 (28.5) and 17.7 (24.9), respectively]. The estimated annual cost per patient was USD 4034. Direct medical costs accounted for 87.7% of this estimate, direct non-medical costs for 2.4%, and indirect costs for 9.9%.ConclusionsResults evidenced that moderate to severe plaque psoriasis imposes substantial costs to society. Our data showed that this disease negatively affects both work productivity and HRQoL of Brazilian patients. Subgroups with PsA and biologic-naïve patients presented lower HRQoL, showing the impact of this comorbidity and the relevance of biologics in psoriasis treatment.FundingNovartis Biociências S.A.Electronic supplementary materialThe online version of this article (10.1007/s12325-019-01049-7) contains supplementary material, which is available to authorized users.

show abstract

“… Was Appropriate Statistical Analysis Used? Radtke et al 10 No Yes Yes Yes Yes No Yes Yes Fernández-Torres et al 11 Yes Yes Yes Yes No No Yes Yes Norris et al 15 Yes Yes Yes Yes No No Yes Yes …”

Section: Resultsmentioning

confidence: 99%

“… 14 Cohort Etanercept: 517 Etanercept: 45.1 (± 12.1) 12 months Etanercept: 22.9 (SD: ± 12.1) Etanercept Etanercept: Median 18 (IQR: 13–24) Adalimumab: 1239 Adalimumab: 44.8 (± 12.4) Adalimumab: 22.3 (SD: ± 12.1) Adalimumab Adalimumab: Median 18 (IQR: 13–23) Ustekinumab: 396 Ustekinumab: 46.7 (± 12.3) Ustekinumab: 22.0 (SD: ± 12.1) Ustekinumab Ustekinumab: Median 19 (IQR: 13–24) Norris et al, 2017. 15 Cross sectional Adalimumab: 35 - 24 weeks - Adalimumab - Etanercept: 7 - Etanercept - Infliximab: 5 - Infliximab - Secukinumab: 3 - Secekinumab - Ustekinimab: 59 - Ustekinimab - Frieder et al, 2018. 9 Cohort Adalimumab: 40 mg EOW vs PBO: 1212 - Adalimumab: 40 mg EOW vs PBO: 16 weeks - Adalimumab: 40 mg weekly or EOW vs PBO Inapplicable Infliximab: IV 5 mg/kg vs PBO: 378 Infliximab: IV 5 mg/kg vs PBO: 12 weeks - Infliximab: IV 5 mg/kg vs PBO Inapplicable Etanercept: ...…”

Section: Resultsmentioning

confidence: 99%